Drug-Resistant Microbes As pesky pathogens continue to evolve, new technologies to combat them are emerging, spelling job opportunities for molecular biologists and chemists.
OBSTINATE MICROBES: Margaret Rennels cites strains of pneumococcus resistence to two major drugs.
In addition to saving lives, successful companies stand to gain a significant share of the $23 billion antibiotics market. It's an alluring combination. "In our long-term strategy, everything we're doing now is based on [disease] resistance," remarks William Kohlbrenner, manager of infectious diseases at Pfizer Inc. in New York. That sentiment is echoed throughout much of the pharmaceutical industry, he adds.
A handful of new or improved...